The Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (WRCE) is located in DHHS Region VI, including Texas, New Mexico, Oklahoma, Arkansas, and Louisiana. Dr. David H. Walker is the PI and director for the WRCE. The University of Texas Medical Branch at Galveston (UTMB) is the lead institution. Academic institutions within the WRCE possess remarkable depth and breadth of scientific expertise related to Category A, B, and C priority pathogens and emerging and re-emerging infectious disease agents. From the very beginning, the WRCE leadership has strived to access this expertise and to make the WRCE a genuine cross-institutional Center involving all member states, not just in name or by concentrating projects at a few universities. The fact that over 100 project leaders at 34 different institutions have received funding from the WRCE is a testament to the plural nature of the WRCE program. The sense of collaboration and spirit of cooperation among investigators from traditionally competing institutions was previously unimaginable prior to the establishment of the WRCE in 2003 under Dr. Walker's guidance and strong leadership. The activities of the WRCE are firmly centered on supporting NIAID's Biodefense Research Agenda, and this application reaffirms our commitment to this strategy. The WRCE program is a success, as evaluated by a number of parameters that consider the whole Center as contributing more than the sum of its individual member institutions and investigators. In the assessment of the national RCE Program, several individual Center measurements were provided. They revealed that the WRCE ranked first in the number of organisms studied, total number of projects, number of Pis, additional non- RCE funding stemming from WRCE research, and number of patent applications as compared to the other individual Centers [1]. Our publication rate is also the one of the highest of the Centers. Since the WRCE was originally funded in September 2003, excellent progress has been made toward producing promising leads for biodefense countermeasures. WRCE translational research resulted in a wealth of significant basic biologic research as well, and the two are not mutually exclusive. Publications from WRCE researchers have resulted in new knowledge about the role of capsule in dissemination of inhalational anthrax, anthrax spore germination, rickettsial genes involved in phagosomal escape, the role of nonstructural genes in the replication of Rift Valley fever virus, the genetics of Nipah virus, and Venezuelan equine encephalitis virus host cell entry mechanisms, to name but a few. Additionally, the well characterized animal models developed by the WRCE Small Animal Core, Nonhuman Primate Core, and select project leaders all contributed knowledge about the natural history and pathogenesis of infections, and these investigations are an essential component for supporting applied research. The original WRCE application in 2003 had a very broad thematic structure in the strategic plan. The focus of the WRCE leadership was to fund the very best science and to take full advantage of the diversity of infectious disease and microbiologic expertise in our region. To date, the WRCE has funded 72 research projects and ten cores, including two trans-RCE cores that resided in our region. This work involved 30 different agents, including nine bacteria, 18 viruses, one protozoan, and two toxins. Given the yield in WRCE patents and publications, the institutions and investigators receiving funding, and projects advancing toward tangible products, this strategy served us very well during the first grant cycle. As the WRCE program matured, four themes emerged that logically encompassed the most productive projects that were likely to lead to biodefense countermeasures. The four themes are as follows: 1. Development of Therapeutic Agents for RNA Viruses 2. Platforms for Multiplexed Diagnostics for Category A-C Agents and Emerging Agents 3. Vaccine Development for Arboviral and Emerging Viral Diseases 4. Vaccine Development for Diseases Caused by Intracellular Bacteria These themes will no doubt serve to help us converge and synergize as we embark on the next leg of our research journey within the WRCE

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057156-10
Application #
8440789
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2015-02-28
Support Year
10
Fiscal Year
2013
Total Cost
$683,169
Indirect Cost
$100,971
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Paterson, Andrew S; Raja, Balakrishnan; Garvey, Gavin et al. (2014) Persistent luminescence strontium aluminate nanoparticles as reporters in lateral flow assays. Anal Chem 86:9481-8
Santiago, Felix W; Covaleda, Lina M; Sanchez-Aparicio, Maria T et al. (2014) Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type I interferon responses. J Virol 88:4572-85
Pflughoeft, Kathryn J; Swick, Michelle C; Engler, David A et al. (2014) Modulation of the Bacillus anthracis secretome by the immune inhibitor A1 protease. J Bacteriol 196:424-35
Lavinder, Jason J; Wine, Yariv; Giesecke, Claudia et al. (2014) Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A 111:2259-64
Valbuena, Gustavo; Halliday, Hailey; Borisevich, Viktoriya et al. (2014) A human lung xenograft mouse model of Nipah virus infection. PLoS Pathog 10:e1004063
Nieves, Wildaliz; Petersen, Hailey; Judy, Barbara M et al. (2014) A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol 21:747-54
Gardner, Christina L; Hritz, Jozef; Sun, Chengqun et al. (2014) Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis 8:e2719
Litvinov, Julia; Hagström, Anna E V; Lopez, Yubitza et al. (2014) Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation. Biotechnol Lett 36:1863-8
Caro-Gomez, Erika; Gazi, Michal; Goez, Yenny et al. (2014) Discovery of novel cross-protective Rickettsia prowazekii T-cell antigens using a combined reverse vaccinology and in vivo screening approach. Vaccine 32:4968-76
Georgiou, George; Ippolito, Gregory C; Beausang, John et al. (2014) The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol 32:158-68

Showing the most recent 10 out of 303 publications